Drug Approval | April 20, 2022
BDR Pharmaceuticals launch Furmecil to treat advanced gastric cancer
The launch is yet another first of its kind innovation in India
The launch is yet another first of its kind innovation in India
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
One of the most advanced cancer care centres in the state of Odisha, it is equipped with the latest technology and a highly experienced multi-disciplinary team of oncologists
Recommendation is based on pivotal data from the phase III POLARIX study
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
